Reich K, Gooderham M, Thaçi D, et al. - Via IMMvent—a phase 3, randomized, double-blind, active-comparator-controlled trial that was completed at 66 clinics in 11 countries and involved 605 adults with moderate-to-severe chronic plaque psoriasis—researchers compared the efficiency and safety of risankizumab with adalimumab in patients with moderate-to-severe plaque psoriasis. In patients with moderate-to-severe plaque psoriasis, risankizumab demonstrated significantly higher efficiency than adalimumab in providing skin clearance. For patients who switched from adalimumab to risankizumab, no additional safety concerns were noted. Moreover, treatment with risankizumab offered flexibility in the long-term treatment of psoriasis.